JP2024519450A5 - - Google Patents

Info

Publication number
JP2024519450A5
JP2024519450A5 JP2023563935A JP2023563935A JP2024519450A5 JP 2024519450 A5 JP2024519450 A5 JP 2024519450A5 JP 2023563935 A JP2023563935 A JP 2023563935A JP 2023563935 A JP2023563935 A JP 2023563935A JP 2024519450 A5 JP2024519450 A5 JP 2024519450A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
use according
antibody
galectin
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519450A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/027127 external-priority patent/WO2022232641A1/en
Publication of JP2024519450A publication Critical patent/JP2024519450A/ja
Publication of JP2024519450A5 publication Critical patent/JP2024519450A5/ja
Pending legal-status Critical Current

Links

JP2023563935A 2021-04-30 2022-04-29 抗ガレクチン-9抗体及びその治療的使用 Pending JP2024519450A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163182521P 2021-04-30 2021-04-30
US63/182,521 2021-04-30
US202163193357P 2021-05-26 2021-05-26
US63/193,357 2021-05-26
US202263313879P 2022-02-25 2022-02-25
US63/313,879 2022-02-25
PCT/US2022/027127 WO2022232641A1 (en) 2021-04-30 2022-04-29 Anti-galectin-9 antibodies and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
JP2024519450A JP2024519450A (ja) 2024-05-14
JP2024519450A5 true JP2024519450A5 (cg-RX-API-DMAC7.html) 2025-05-09

Family

ID=83847350

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563935A Pending JP2024519450A (ja) 2021-04-30 2022-04-29 抗ガレクチン-9抗体及びその治療的使用

Country Status (8)

Country Link
US (1) US20240190970A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329807A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024519450A (cg-RX-API-DMAC7.html)
AU (1) AU2022266821A1 (cg-RX-API-DMAC7.html)
CA (1) CA3217822A1 (cg-RX-API-DMAC7.html)
IL (1) IL308014A (cg-RX-API-DMAC7.html)
WO (1) WO2022232641A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202309775B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019084553A1 (en) 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
CN119033928A (zh) * 2019-05-01 2024-11-29 纽约大学 抗半乳糖凝集素-9抗体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102537A1 (es) * 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
WO2019084553A1 (en) * 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
CA3134942A1 (en) * 2019-03-25 2020-10-01 New York University Anti-galectin-9 antibodies and uses thereof
CN119033928A (zh) * 2019-05-01 2024-11-29 纽约大学 抗半乳糖凝集素-9抗体及其用途
WO2021022256A1 (en) * 2019-08-01 2021-02-04 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
CN116782934A (zh) * 2020-10-26 2023-09-19 纯技术Lyt股份有限公司 抗半乳糖凝集素9抗体及其在治疗眼部黑素瘤中的用途
WO2022109302A1 (en) * 2020-11-20 2022-05-27 New York University Anti-galectin-9 antibodies and therapeutic uses thereof
US20240109968A1 (en) * 2020-11-20 2024-04-04 New York University Anti-galectin-9 antibodies and therapeutic uses thereof

Similar Documents

Publication Publication Date Title
JP2021514969A5 (cg-RX-API-DMAC7.html)
JP2021513540A5 (cg-RX-API-DMAC7.html)
JP2022531408A5 (cg-RX-API-DMAC7.html)
JP2020508317A5 (cg-RX-API-DMAC7.html)
JP2018518454A5 (cg-RX-API-DMAC7.html)
JP2021510697A5 (cg-RX-API-DMAC7.html)
JP2018519327A5 (cg-RX-API-DMAC7.html)
JP2017533912A5 (cg-RX-API-DMAC7.html)
JP2022543780A5 (cg-RX-API-DMAC7.html)
EP3258965A2 (en) Combination therapy for cancer treatment
JP2022512851A5 (cg-RX-API-DMAC7.html)
JPWO2022270524A5 (cg-RX-API-DMAC7.html)
TW202313694A (zh) 治療癌症以及腫瘤相關之體重減輕及惡病質之方法
WO2025103379A1 (zh) 抗b7h3抗体-药物偶联物治疗癌症的方法
RU2017142804A (ru) Лечение пациентов с диагнозом аденокарцинома поджелудочной железы с использованием моноклональных антител к рецептору эпидермального фактора роста (egfr)
Shukla et al. Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer
JP2021511344A5 (cg-RX-API-DMAC7.html)
JP2022530599A5 (cg-RX-API-DMAC7.html)
JP2024519449A5 (cg-RX-API-DMAC7.html)
JP2021529777A5 (cg-RX-API-DMAC7.html)
CN109806393B (zh) 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途
JP2024536383A5 (cg-RX-API-DMAC7.html)
WO2021213523A1 (zh) 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
CN117815387A (zh) Cdk4/6抑制剂和抗pd-l1抗体的联用药物组合物
JPWO2022270523A5 (cg-RX-API-DMAC7.html)